New · CUSIP 640268306 · who reports it, how much, and how much it matters to them
34 of the 720 hedge fund managers we track reported shares of Nektar Therapeutics (Nasdaq: NKTR) on Form 13F for 30 June 2026. Between them they reported USD 402m. The largest position belongs to Two Sigma Investments, at USD 84m. The manager with the most riding on it is 22NW, where it is 18.7% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Two Sigma Investments35 funds on PPLI.com | USD 84m | 0.1% |
| 2 | Armistice Capital1 fund on PPLI.com | USD 51m | 0.6% |
| 3 | Millennium Management6 funds on PPLI.com | USD 33m | 0.0% |
| 4 | Braidwell12 funds on PPLI.com | USD 33m | 1.2% |
| 5 | Sofinnova Investments1 fund on PPLI.com | USD 33m | 1.7% |
| 6 | Orbimed Advisors1 fund on PPLI.com | USD 32m | 0.6% |
| 7 | Dafna Capital Management6 funds on PPLI.com | USD 22m | 4.2% |
| 8 | Deep Track Capital1 fund on PPLI.com | USD 21m | 0.3% |
| 9 | 22NW1 fund on PPLI.com | USD 20m | 18.7% |
| 10 | Bronte Capital Management Pty3 funds on PPLI.com | USD 14m | 1.5% |
| 11 | Great Point Partners2 funds on PPLI.com | USD 12m | 2.3% |
| 12 | Citadel Advisors32 funds on PPLI.com | USD 11m | 0.0% |
| 13 | LMR Partners2 funds on PPLI.com | USD 7m | 0.0% |
| 14 | Exoduspoint Capital Management7 funds on PPLI.com | USD 4.1m | 0.0% |
| 15 | Landscape Capital Management4 funds on PPLI.com | USD 2.9m | 0.2% |
| 16 | Voleon Capital Management13 funds on PPLI.com | USD 2.9m | 0.1% |
| 17 | Anson Funds Management8 funds on PPLI.com | USD 2.8m | 0.2% |
| 18 | Atom Investors1 fund on PPLI.com | USD 2.8m | 0.3% |
| 19 | Burkehill Global Management5 funds on PPLI.com | USD 2.8m | 0.1% |
| 20 | Exome Asset Management2 funds on PPLI.com | USD 1.6m | 1.0% |
| 21 | Brevan Howard Capital Management39 funds on PPLI.com | USD 1.5m | 0.0% |
| 22 | Awm Investment Company6 funds on PPLI.com | USD 1.5m | 0.1% |
| 23 | Engineers Gate Manager1 fund on PPLI.com | USD 1.3m | 0.0% |
| 24 | Diametric Capital2 funds on PPLI.com | USD 1.1m | 0.1% |
| 25 | HighVista Strategies27 funds on PPLI.com | USD 608,000 | 0.1% |
| 26 | Persistent Asset Partners10 funds on PPLI.com | USD 522,000 | 0.2% |
| 27 | Rangeley Capital6 funds on PPLI.com | USD 489,000 | 0.4% |
| 28 | Capstone Investment Advisors25 funds on PPLI.com | USD 482,000 | 0.0% |
| 29 | Squarepoint Ops7 funds on PPLI.com | USD 405,000 | 0.0% |
| 30 | Marshall Wace LLP84 funds on PPLI.com | USD 230,000 | 0.0% |
| 31 | The Quarry1 fund on PPLI.com | USD 227,000 | 0.0% |
| 32 | Bayforest Capital1 fund on PPLI.com | USD 158,000 | 0.1% |
| 33 | Freestone Grove Partners1 fund on PPLI.com | USD 155,000 | 0.0% |
| 34 | Elequin Capital2 funds on PPLI.com | USD 3,909 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | 22NW | USD 20m | 18.7% |
| 2 | Dafna Capital Management | USD 22m | 4.2% |
| 3 | Great Point Partners | USD 12m | 2.3% |
| 4 | Sofinnova Investments | USD 33m | 1.7% |
| 5 | Bronte Capital Management Pty | USD 14m | 1.5% |
| 6 | Braidwell | USD 33m | 1.2% |
| 7 | Exome Asset Management | USD 1.6m | 1.0% |
| 8 | Armistice Capital | USD 51m | 0.6% |
| 9 | Orbimed Advisors | USD 32m | 0.6% |
| 10 | Rangeley Capital | USD 489,000 | 0.4% |
Nektar Therapeutics trades under the symbol NKTR on the Nasdaq. Its CUSIP, the code used on Form 13F, is 640268306.
34 of the 720 hedge fund managers PPLI.com tracks reported Nektar Therapeutics shares on Form 13F for 30 June 2026. The largest reported positions were held by Two Sigma Investments (USD 84m), Armistice Capital (USD 51m), Millennium Management (USD 33m), Braidwell (USD 33m) and Sofinnova Investments (USD 33m).
34 managers in our coverage reported it, and between them they run 355 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
22NW, where the position was 18.7% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Nektar Therapeutics or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.